Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective.
Prisciandaro M, Antista M, Raimondi A, Corti F, Morano F, Centonze G, Sabella G, Mangogna A, Randon G, Pagani F, Prinzi N, Niger M, Corallo S, Castiglioni di Caronno E, Massafra M, Bartolomeo MD, de Braud F, Milione M, Pusceddu S. Prisciandaro M, et al. Among authors: bartolomeo md. Front Oncol. 2022 Feb 4;12:780716. doi: 10.3389/fonc.2022.780716. eCollection 2022. Front Oncol. 2022. PMID: 35186729 Free PMC article. Review.
Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
Zaniboni A, Barone CA, Banzi MC, Bergamo F, Blasi L, Bordonaro R, Bartolomeo MD, Costanzo FD, Frassineti GL, Garufi C, Giuliani F, Latiano TP, Martinelli E, Personeni N, Racca P, Tamburini E, Tonini G, Besse MG, Spione M, Falcone A. Zaniboni A, et al. Among authors: bartolomeo md. Future Oncol. 2021 Jun;17(18):2315-2324. doi: 10.2217/fon-2020-1278. Epub 2021 Mar 5. Future Oncol. 2021. PMID: 33663264 Clinical Trial.
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
Cremolini C, Antoniotti C, Pietrantonio F, Berenato R, Tampellini M, Baratelli C, Salvatore L, Marmorino F, Borelli B, Nichetti F, Bironzo P, Sonetto C, Bartolomeo MD, Braud F, Loupakis F, Falcone A, Di Maio M. Cremolini C, et al. Among authors: bartolomeo md. Cancer Res Treat. 2017 Jul;49(3):834-845. doi: 10.4143/crt.2016.249. Epub 2016 Nov 15. Cancer Res Treat. 2017. PMID: 27857020 Free PMC article. Review.
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.
Hill AG, Findlay MP, Burge ME, Jackson C, Alfonso PG, Samuel L, Ganju V, Karthaus M, Amatu A, Jeffery M, Bartolomeo MD, Bridgewater J, Coveler AL, Hidalgo M, Kapp AV, Sufan RI, McCall BB, Hanley WD, Penuel EM, Pirzkall A, Tabernero J. Hill AG, et al. Among authors: bartolomeo md. Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5. Clin Cancer Res. 2018. PMID: 29506988 Clinical Trial.
Corrigendum to 'Hypotonic Infant with PURA Syndrome-related Channelopathy Successfully Treated with Pyridostigmine' Neuromuscular Disorders Volume 32, Issue 2, February 2022, Pages 166-169.
Wyrebek R, Bartolomeo MD, Brooks S, Geller T, Crenshaw M, Iyadurai S. Wyrebek R, et al. Among authors: bartolomeo md. Neuromuscul Disord. 2022 Aug;32(8):e1. doi: 10.1016/j.nmd.2022.06.008. Epub 2022 Jul 21. Neuromuscul Disord. 2022. PMID: 35871129 No abstract available.